1800-272-662
Shopping Cart 0
countryflagAU
Login

Shattuck Labs Inc

Healthcare US STTK

5.96USD
-0.06(1.00%)

Last update at 2026-03-10T20:26:00Z

Day Range

5.846.25
LowHigh

52 Week Range

1.3311.76
LowHigh

Fundamentals

  • Previous Close 6.02
  • Market Cap348.55M
  • Volume432037
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-86.03800M
  • Revenue TTM2.71M
  • Revenue Per Share TTM0.06
  • Gross Profit TTM -82.24700M
  • Diluted EPS TTM-1.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -101.94500M -44.97400M -36.60300M -23.98200M -7.38800M
Minority interest - - - - -
Net income -100.56100M -44.34900M -35.43600M -23.88300M -7.38800M
Selling general administrative 21.08M 18.72M 9.38M 5.74M 3.78M
Selling and marketing expenses - - - - -
Gross profit 0.65M 30.02M 9.93M 9.89M 22.44M
Reconciled depreciation 3.07M 1.38M 0.62M 0.54M 0.26M
Ebit -106.40200M -45.26900M -37.54900M -25.06700M -5.53900M
Ebitda -103.32900M -43.88900M -36.93100M -23.44500M -5.28400M
Depreciation and amortization 3.07M 1.38M 0.62M 1.62M 0.26M
Non operating income net other 1.38M 0.29M 0.33M - -
Operating income -103.32900M -45.26900M -36.93100M -25.06700M -6.14800M
Other operating expenses 103.98M 75.29M 46.87M 34.95M 28.59M
Interest expense -3.07300M 1.38M 0.00000M 0.00000M 2.63M
Tax provision - - - - -
Interest income 1.59M 0.62M 0.55M 1.18M 0.97M
Net interest income 1.59M 0.62M 0.55M 1.18M -1.66500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.38400M -0.62500M -1.16700M -0.09900M 1.39M
Total revenue 0.65M 30.02M 9.93M 9.89M 22.44M
Total operating expenses 103.98M 75.29M 46.87M 34.95M 28.59M
Cost of revenue - - - - -
Total other income expense net 1.38M 0.29M 0.33M 1.08M 0.42M
Discontinued operations - - - - -
Net income from continuing ops -101.94500M -44.97400M -36.60300M -23.98200M -7.38800M
Net income applicable to common shares -101.94500M -44.97400M -36.60300M -23.98200M -7.38800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 159.56M 205.32M 298.58M 348.99M 44.97M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 12.60M 23.30M 19.46M 10.19M 3.35M
Total liab 14.86M 29.17M 26.80M 39.13M 79.52M
Total stockholder equity 144.71M 176.16M 271.79M 309.86M -34.54800M
Deferred long term liab - - 2.21M 0.99M -
Other current liab 9.07M 17.80M 14.57M 0.42M 0.42M
Common stock 0.00500M 0.00500M 0.00500M 0.00500M 0.00100M
Capital stock 0.00500M 0.00500M 0.00500M 0.00500M 0.00100M
Retained earnings -306.31000M -219.01200M -117.06700M -72.09300M -35.49000M
Other liab - - 2.21M 22.29M 10.47M
Good will - - - - -
Other assets 0.00000M 0.43M 10.32M 0.35M 0.09M
Cash 125.63M 47.38M 92.27M 157.90M 7.01M
Cash and equivalents - - - - -
Total current liabilities 11.45M 24.96M 24.59M 16.83M 19.98M
Current deferred revenue - - - 7.73M 12.89M
Net debt -121.42400M -43.17700M -92.26800M -157.89800M -7.01300M
Short term debt 0.80M - - 6.93M 3.61M
Short long term debt - - - - -
Short long term debt total 4.20M 4.20M - - -
Other stockholder equity 451.01M 396.04M 389.41M 33.02M 0.89M
Property plant equipment - 17.67M 9.94M 3.00M 2.44M
Total current assets 143.22M 184.58M 288.27M 345.64M 42.44M
Long term investments - - - - -
Net tangible assets - 176.16M 271.79M 309.86M -34.54800M
Short term investments 5.00M 113.90M 176.54M 177.55M 32.07M
Net receivables - 3.07M 0.38M 2.60M -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.59M 7.17M 10.01M 1.75M 3.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00400M -0.87700M -0.56000M -0.06300M 0.05M
Additional paid in capital - - - - -
Common stock total equity - 0.00500M 0.00500M 0.00500M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -219.01200M -117.06700M -72.09300M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.54M 3.07M 0.38M 0.35M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 16.34M 20.74M 10.32M 3.35M 2.53M
Capital lease obligations 4.20M 4.20M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 60.95M -2.51700M -145.59500M -3.12200M -28.73200M
Change to liabilities 0.13M 14.79M 4.82M -1.96300M 0.61M
Total cashflows from investing activities 49.44M -10.44300M -146.32200M -3.59200M -29.92500M
Net borrowings - - - - -
Total cash from financing activities 0.17M 1.93M 330.87M -0.06400M 35.15M
Change to operating activities -1.62200M -0.85600M -3.75900M 4.14M -3.10400M
Net income -101.94500M -44.97400M -36.60300M -23.98200M -7.38800M
Change in cash -44.88900M -65.63000M 150.88M -24.63100M -1.68300M
Begin period cash flow 92.27M 157.90M 7.01M 31.64M 33.33M
End period cash flow 47.38M 92.27M 157.90M 7.01M 31.64M
Total cash from operating activities -94.49800M -57.11600M -33.65900M -20.97500M -6.90300M
Issuance of capital stock - 0.00000M 349.92M 0.00000M 35.30M
Depreciation 3.07M 1.38M 0.62M 0.54M 0.26M
Other cashflows from investing activities 0.10M - - - -0.01500M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.17M 1.93M 213.25M - -
Other cashflows from financing activities 49.44M 1.93M 98.56M -0.06400M 35.15M
Change to netincome 7.17M 5.47M 1.27M 0.29M 2.73M
Capital expenditures 11.61M 7.93M 0.73M 0.47M 1.18M
Change receivables - - - - -
Cash flows other operating -4.29500M -36.81400M -0.50200M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -44.88900M -65.63000M 150.88M - -
Change in working capital -4.46400M -23.54800M 0.97M 2.22M -2.49600M
Stock based compensation 6.46M 5.47M 1.27M 0.46M 0.42M
Other non cash items 2.38M 1.52M 0.09M -0.04100M 2.71M
Free cash flow -106.11200M -65.04200M -34.38600M -21.44500M -8.08100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
STTK
Shattuck Labs Inc		 -0.06 1.00% 5.96 - - 267.60 3.07 192.16 -3.6219
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs Inc

500 West 5th Street, Austin, TX, United States, 78701

Key Executives

Name Title Year Born
Dr. Taylor H. Schreiber M.D., Ph.D. Co-Founder, CEO & Director 1980
Dr. Arundathy Nirmalini Pandite M.B.A., M.D. Chief Medical Officer 1959
Ms. Casi DeYoung Chief Bus. Officer 1971
Mr. Andrew R. Neill M.B.A. Chief Financial Officer 1986
Conor Richardson Sr. Director of Fin. & Investor Relations NA
Dr. Abhinav A. Shukla Ph.D. Chief Technical Officer 1973
Ms. Erin Ator Thomson J.D. Gen. Counsel, Corp. Sec. and Chief Ethics & Compliance Officer 1980
Dr. Thomas Lampkin Pharm.D. Sr. VP of Regulatory Affairs NA
Ms. Fatima Rangwala M.D., Ph.D. Sr. VP of Clinical Research NA
Dr. Arundathy Nirmalini Pandite M.B.A., M.D. Chief Medical Officer 1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.